Trial Profile

Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemtuzumab ozogamicin (Primary) ; Oblimersen (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Sponsors Genta

Most Recent Events

10 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
10 Jan 2014 Planned number of patients changed from 20 to 100 as ClinicalTrials.gov reports planned patient no 20 -100, so considered highest number
14 Apr 2009 Actual end date (1 Dec 2000) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com